Correction: EGFR Kinase Domain Mutation Positive Lung Cancers Are Sensitive to Intrapleural Perfusion with Hyperthermic Chemotherapy (IPHC) Complete Treatment.

Hongjuan Zhang,Cheng Zhan,Ji Ke,Zhiqiang Xue,Aiqun Zhang,Kaifeng Xu,Zhirong Shen,Lei Yu,Liang Chen

DOI: https://doi.org/10.18632/oncotarget.26255

2018-01-01

Oncotarget

Abstract:[This corrects the article DOI: 10.18632/oncotarget.6491.].

What problem does this paper attempt to address?

EGFR Kinase Domain Mutation Positive Lung Cancers Are Sensitive to Intrapleural Perfusion with Hyperthermic Chemotherapy (IPHC) Complete Treatment.

Hongjuan Zhang,Cheng Zhan,Ji Ke,Zhiqiang Xue,Aiqun Zhang,Kaifeng Xu,Zhirong Shen,Lei Yu,Liang Chen

DOI: https://doi.org/10.18632/oncotarget.6491

2015-01-01

Oncotarget

Abstract:Lung cancer is the global leading cause of cancer-related deaths. A significant portion of lung cancer patients harbor kinase domain mutations in the epidermal growth factor receptor (EGFR). While EGFR tyrosine kinase inhibitors (TKI) effectively shrink tumors harboring mutant EGFR, clinical efficacy is limited by the development of TKI resistance. Effective alternatives are desperately needed in clinic for treating EGFR kinase domain mutation positive lung cancer. In our clinic in treating M1a lung cancer patients through intrapleural perfusion with hyperthermic chemotherapy (IPHC) followed by cycles of systemic chemotherapy (we termed this procedure IPHC complete treatment, IPHC-CT), we found dramatic tumor shrinkage in mutant EGFR-positive patients. We further confirmed the sensitivity of EGFR mutation-positive lung cancer cell lines derived from patients to HC (hyperthermic chemotherapy) treatment. We found that hyperthermia promoted accumulation of cisplatin in lung cancer cells. Hyperthermia and cisplatin synergistically downregulated the EGFR protein level, leading to quenching of signal from EGFR and induction of apoptosis. Our work therefore showed IPHC-CT is an effective treatment for EGFR kinase domain mutation positive lung cancer patients.
Erratum: Targeting NF-κB/AP-2β Signaling to Enhance Antitumor Activity of Cisplatin by Melatonin in Hepatocellular Carcinoma Cells.

Jiaojiao Hao,Zhenglin Li,Changlin Zhang,Wendan Yu,Zhipeng Tang,Yixin Li,Xu Feng,Yue Gao,Quentin Liu,Wenlin Huang,Wei Guo,Wuguo Deng

DOI: https://doi.org/10.62347/suki5933

2024-01-01

American journal of cancer research

Abstract:[This corrects the article on p. 13 in vol. 7, PMID: 28123844.].
Correction: the Combination Effect of Homoharringtonine and Ibrutinib on FLT3-ITD Mutant Acute Myeloid Leukemia

Xia Li,Xiufeng Yin,Huafeng Wang,Jiansong Huang,Mengxia Yu,Zhixin Ma,Chenying Li,Yile Zhou,Xiao Yan,ShuJuan Huang,Jie Jin

DOI: https://doi.org/10.18632/oncotarget.27310

2019-01-01

Oncotarget

Abstract:[This corrects the article DOI: 10.18632/oncotarget.14463.].
Correction: Clinical Significance and Effect of AEG-1 on the Proliferation, Invasion, and Migration of NSCLC: a Study Based on Immunohistochemistry, TCGA, Bioinformatics, in Vitro and in Vivo Verification.

Yu Zhang,Zu-Yun Li,Xin-Xi Hou,Xiao Wang,Yi-Huan Luo,Yan-Ping Ying,Gang Chen

DOI: https://doi.org/10.18632/oncotarget.28212

2022-01-01

Oncotarget

Abstract:[This corrects the article DOI: 10.18632/oncotarget.14972.].
Erratum: Hepatic Carcinoma with Indolent T-lymphoblastic Proliferation (It-Lbp).

Mei Kong,Zhaoming Wang,Xiaodong Teng,Liming Xu,Jimin Liu,Chenyang Jiang,Lisong Teng

2019-01-01

Abstract:[This corrects the article on p. 1674 in vol. 11, PMID: 31938268.].
Correction: Tumor Driven by Gain-of-function HER2 H878Y Mutant is Highly Sensitive to HER2 Inhibitor.

Zexi Hu,Yong Hu,Xicheng Liu,Rongwen Xi,Aiqun Zhang,Deruo Liu,Qiang Xie,Liang Chen

DOI: https://doi.org/10.18632/oncotarget.26252

2018-01-01

Oncotarget

Abstract:[This corrects the article DOI: 10.18632/oncotarget.5221.].
Correction: Overexpression of Wildtype EGFR is Tumorigenic and Denotes a Therapeutic Target in Non-Small Cell Lung Cancer

Naiqing Xu,Wenfeng Fang,Libing Mu,Yanna Tang,Lei Gao,Shengxiang Ren,Dengfeng Cao,Lei Zhou,Aiqun Zhang,Deruo Liu,Caicun Zhou,Kwok-Kin Wong,Lei Yu,Li Zhang,Chaozhao Liang

DOI: https://doi.org/10.18632/oncotarget.26254

2018-01-01

Oncotarget

Abstract:[This corrects the article DOI: 10.18632/oncotarget.6461.].
Author Correction: Mechanisms and clinical activity of an EGFR and HER2 exon 20–selective kinase inhibitor in non–small cell lung cancer

Jacqulyne P. Robichaux,Yasir Y. Elamin,Zhi Tan,Brett W. Carter,Shuxing Zhang,Shengwu Liu,Shuai Li,Ting Chen,Alissa Poteete,Adriana Estrada-Bernal,Anh T. Le,Anna Truini,Monique B. Nilsson,Huiying Sun,Emily Roarty,Sarah B. Goldberg,Julie R. Brahmer,Mehmet Altan,Charles Lu,Vassiliki Papadimitrakopoulou,Katerina Politi,Robert C. Doebele,Kwok-Kin Wong,John V. Heymach

DOI: https://doi.org/10.1038/s41591-024-03178-1

IF: 82.9

2024-08-22

Nature Medicine

Abstract:Nature Medicine, Published online: 20 August 2024; doi:10.1038/s41591-024-03178-1 Author Correction: Mechanisms and clinical activity of an EGFR and HER2 exon 20–selective kinase inhibitor in non–small cell lung cancer

biochemistry & molecular biology,cell biology,medicine, research & experimental
Correction: Infiltrating Mast Cells Increase Prostate Cancer Chemotherapy and Radiotherapy Resistances Via Modulation of P38/p53/p21 and ATM Signals.

Hongjun Xie,Chong Li,Qiang Dang,Luke S Chang,Lei Li

DOI: https://doi.org/10.18632/oncotarget.27023

2019-01-01

Oncotarget

Abstract:[This corrects the article DOI: 10.18632/oncotarget.6372.].
Combined Photodynamic and Photothermal Therapy and Immunotherapy for Cancer Treatment: A Review [Corrigendum]

Cunqing Kong,Xingcai Chen

DOI: https://doi.org/10.2147/ijn.s422584

IF: 7.033

2023-05-01

International Journal of Nanomedicine

Abstract:[This corrects the article DOI: 10.2147/IJN.S388996.].

pharmacology & pharmacy,nanoscience & nanotechnology
Correction: Inhibition of HIF-1α by PX-478 enhances the anti-tumor effect of gemcitabine by inducing immunogenic cell death in pancreatic ductal adenocarcinoma (Oncotarget (2015) 6 (2250–2262) DOI: 10.18632/oncotarget.2948)

Tiansuo Zhao,He Ren,Li Jia,Jing Chen,Wen Xin,Fan Yan,Jing Li,Xiuchao Wang,Song Gao,Dong Qian,Chongbiao Huang,Jihui Hao

DOI: https://doi.org/10.18632/oncotarget.27205

2019-01-01

Oncotarget

Abstract:[This corrects the article DOI: 10.18632/oncotarget.2948.].
Correction: Real-world Management of Patients with Epidermal Growth Factor Receptor (EGFR) Mutation-Positive Non-Small-cell Lung Cancer in the USA

Yulin Li,Anita Appius,Thirupathi Pattipaka,Andrea Feyereislova,Adrian Cassidy,Apar Kishor Ganti

DOI: https://doi.org/10.1371/journal.pone.0212831

IF: 3.7

2019-01-01

PLoS ONE

Abstract:[This corrects the article DOI: 10.1371/journal.pone.0209709.].
Corrigendum: EGFR Tyrosine Kinase Inhibitors Versus Chemotherapy As First-Line Therapy for Non-Small Cell Lung Cancer Patients with the L858R Point Mutation.

Jianlin Xu,Haitang Yang,Bo Jin,Yuqing Lou,Yanwei Zhang,Xueyan Zhang,Hua Zhong,Huiming Wang,Dan Wu,Baohui Han

DOI: https://doi.org/10.1038/srep38270

IF: 4.6

2016-01-01

Scientific Reports

Abstract:Scientific Reports 6: Article number: 36371; published online: 04 November 2016; updated: 01 December 2016
Correction: Solitary Ground-Glass Opacity Nodules of Stage IA Pulmonary Adenocarcinoma: Combination of 18F-FDG PET/CT and High-Resolution Computed Tomography Features to Predict Invasive Adenocarcinoma.

Jun Zhou,Yanli Li,Yiqiu Zhang,Guobing Liu,Hui Tan,Yan Hu,Jie Xiao,Hongcheng Shi

DOI: https://doi.org/10.18632/oncotarget.26671

2019-01-01

Oncotarget

Abstract:[This corrects the article DOI: 10.18632/oncotarget.15577.].
Corrigendum: Targeting HER3 to overcome RGFR TKI resistance in NSCLC

Qiuqiang Chen,Gang Jia,Xilin Zhang,Wenxue Ma

DOI: https://doi.org/10.3389/fimmu.2024.1376045

IF: 7.3

2024-01-31

Frontiers in Immunology

Abstract:[This corrects the article DOI: 10.3389/fimmu.2023.1332057.].

immunology
Overcoming erlotinib resistance in EGFR mutation-positive lung adenocarcinomas through repression of phosphoglycerate dehydrogenase: Erratum

Jiang-Kai Dong,Hui-Min Lei,Qian Liang,Ya-Bin Tang,Ye Zhou,Yang Wang,Shengzhe Zhang,Wen-Bin Li,Yunguang Tong,Guanglei Zhuang,Liang Zhang,Hong-Zhuan Chen,Liang Zhu,Ying Shen

DOI: https://doi.org/10.7150/thno.58558

IF: 11.6

2021-01-01

Theranostics

Abstract:[This corrects the article DOI: 10.7150/thno.23177.].

medicine, research & experimental
Correction To: Targeted Therapy for Cisplatin‐resistant Lung Cancer Via Aptamer‐guided Nano‐zinc Carriers Containing USP14 Sirna

Xinmin Zhao,Xianghua Wu,Huijie Wang,Songtao Lai,Jialei Wang

DOI: https://doi.org/10.1002/mco2.237

2023-01-01

MedComm

Abstract:[This corrects the article DOI: 10.1002/mco2.237.].
Correction: Cepharanthine Hydrochloride Reverses the Mdr1 (P-Glycoprotein)-mediated Esophageal Squamous Cell Carcinoma Cell Cisplatin Resistance Through JNK and P53 Signals

Pengjun Zhou,Rong Zhang,Ying Wang,Dandan Xu,Li Zhang,Jinhong Qin,Guifeng Su,Yue Feng,Hongce Chen,Siyuan You,Wen Rui,Huizhong Liu,Suhong Chen,Hongyuan Chen,Yifei Wang

DOI: https://doi.org/10.18632/oncotarget.27638

2021-01-01

Oncotarget

Abstract:[This corrects the article DOI: 10.18632/oncotarget.22676.].
Corrigendum: the Significance of Transarterial Chemo(embolization) Combined with Tyrosine Kinase Inhibitors and Immune Check Point Inhibitors for Unresectable Hepatocellular Carcinoma in the Era of Systemic Therapy: A Systematic Review

Qiao Ke,Fuli Xin,Huipeng Fang,Yongyi Zeng,Lei Wang,Jingfeng Liu

DOI: https://doi.org/10.3389/fimmu.2022.952446

IF: 7.3

2022-01-01

Frontiers in Immunology

Abstract:[This corrects the article DOI: 10.3389/fimmu.2022.913464.].
Erratum: Overcome trastuzumab resistance of breast cancer using anti-HER2 chimeric antigen receptor T cells and PD1 blockade.

Hongzhi Li,Weihua Yuan,Shufang Bin,Guang Wu,Panyuan Li,Min Liu,Jifeng Yang,Xiang Li,Kaiyan Yang,Haihua Gu

2022-01-01

American journal of cancer research

Abstract:[This corrects the article on p. 688 in vol. 10, PMID: 32195036.].

Correction: EGFR Kinase Domain Mutation Positive Lung Cancers Are Sensitive to Intrapleural Perfusion with Hyperthermic Chemotherapy (IPHC) Complete Treatment.

EGFR Kinase Domain Mutation Positive Lung Cancers Are Sensitive to Intrapleural Perfusion with Hyperthermic Chemotherapy (IPHC) Complete Treatment.

Erratum: Targeting NF-κB/AP-2β Signaling to Enhance Antitumor Activity of Cisplatin by Melatonin in Hepatocellular Carcinoma Cells.

Correction: the Combination Effect of Homoharringtonine and Ibrutinib on FLT3-ITD Mutant Acute Myeloid Leukemia

Correction: Clinical Significance and Effect of AEG-1 on the Proliferation, Invasion, and Migration of NSCLC: a Study Based on Immunohistochemistry, TCGA, Bioinformatics, in Vitro and in Vivo Verification.

Erratum: Hepatic Carcinoma with Indolent T-lymphoblastic Proliferation (It-Lbp).

Correction: Tumor Driven by Gain-of-function HER2 H878Y Mutant is Highly Sensitive to HER2 Inhibitor.

Correction: Overexpression of Wildtype EGFR is Tumorigenic and Denotes a Therapeutic Target in Non-Small Cell Lung Cancer

Author Correction: Mechanisms and clinical activity of an EGFR and HER2 exon 20–selective kinase inhibitor in non–small cell lung cancer

Correction: Infiltrating Mast Cells Increase Prostate Cancer Chemotherapy and Radiotherapy Resistances Via Modulation of P38/p53/p21 and ATM Signals.

Combined Photodynamic and Photothermal Therapy and Immunotherapy for Cancer Treatment: A Review [Corrigendum]

Correction: Inhibition of HIF-1α by PX-478 enhances the anti-tumor effect of gemcitabine by inducing immunogenic cell death in pancreatic ductal adenocarcinoma (Oncotarget (2015) 6 (2250–2262) DOI: 10.18632/oncotarget.2948)

Correction: Real-world Management of Patients with Epidermal Growth Factor Receptor (EGFR) Mutation-Positive Non-Small-cell Lung Cancer in the USA

Corrigendum: EGFR Tyrosine Kinase Inhibitors Versus Chemotherapy As First-Line Therapy for Non-Small Cell Lung Cancer Patients with the L858R Point Mutation.

Correction: Solitary Ground-Glass Opacity Nodules of Stage IA Pulmonary Adenocarcinoma: Combination of 18F-FDG PET/CT and High-Resolution Computed Tomography Features to Predict Invasive Adenocarcinoma.

Corrigendum: Targeting HER3 to overcome RGFR TKI resistance in NSCLC

Overcoming erlotinib resistance in EGFR mutation-positive lung adenocarcinomas through repression of phosphoglycerate dehydrogenase: Erratum

Correction To: Targeted Therapy for Cisplatin‐resistant Lung Cancer Via Aptamer‐guided Nano‐zinc Carriers Containing USP14 Sirna

Correction: Cepharanthine Hydrochloride Reverses the Mdr1 (P-Glycoprotein)-mediated Esophageal Squamous Cell Carcinoma Cell Cisplatin Resistance Through JNK and P53 Signals

Corrigendum: the Significance of Transarterial Chemo(embolization) Combined with Tyrosine Kinase Inhibitors and Immune Check Point Inhibitors for Unresectable Hepatocellular Carcinoma in the Era of Systemic Therapy: A Systematic Review

Erratum: Overcome trastuzumab resistance of breast cancer using anti-HER2 chimeric antigen receptor T cells and PD1 blockade.